Mirap Distab (Mirtazapine)

Mirtazapine, the active ingredient in Mirap Distab, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral tablet for oral administration. It is prescribed for the treatment of major depressive disorder in adult patients, helping to improve mood, sleep and appetite.

GNH USA supplies Mirap Distab as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides reliable, timely logistics, regulatory support and documentation for cross‑border procurement.

Mirtazapine acts on noradrenergic and serotonergic pathways to treat depressive disorders.

- Major depressive disorder: alleviates depressive symptoms and improves functional outcomes

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Fatigue

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Seizures - Severe hypotension - Hepatic dysfunction - Suicidal ideation, especially early in treatment - Blood dyscrasias such as thrombocytopenia

Mirtazapine requires careful monitoring in several clinical situations. - Assess hepatic function: adjust use in severe liver impairment - Monitor weight: risk of significant weight gain - Screen for suicidal thoughts: especially during initial weeks - Use caution in elderly: increased risk of sedation and falls - Avoid abrupt discontinuation: may cause withdrawal symptoms - Store at ambient temperature: keep in original container, protect from moisture and light

Mirtazapine may interact with several drug classes.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis - Other serotonergic agents (e.g., SSRIs, SNRIs, tramadol): risk of serotonin syndrome - Central nervous system depressants (e.g., benzodiazepines, alcohol): enhanced sedation

Moderate Interactions (Monitor Closely): - Antihypertensives: additive hypotensive effect - Anticholinergic drugs: increased anticholinergic burden - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may raise mirtazapine levels - Carbamazepine: may reduce mirtazapine exposure - Warfarin: monitor INR for potential changes